Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205639 | 0.86 | GPR88 (0.36) | KMT2ASMN1; SMN2MEN1CYP1A2GPR88 | |
| SCHEMBL26205643 | 0.85 | GPR88 (0.35) | CYP1A2GPR88METKDR | |
| SCHEMBL26205631 | 0.81 | MAPT (0.44) | KMT2ASMN1; SMN2MEN1CYP1A2GPR88 | |
| SCHEMBL26205635 | 0.80 | TSHR (0.42) | KMT2AMEN1 | |
| SCHEMBL26205633 | 0.79 | HSD17B10 (0.48) | KMT2ASMN1; SMN2 | |
| SCHEMBL26205636 | 0.78 | CYP1A2 (0.35) | CYP1A2MCL1GPR88 | |
| SCHEMBL22526236 | 0.78 | AAK1 (0.48) | KMT2AMEN1 | |
| SCHEMBL26206369 | 0.77 | FFAR4 (0.39) | MCL1 | |
| SCHEMBL26205646 | 0.75 | PTGER1 (0.33) | KMT2ASMN1; SMN2MEN1CYP1A2MET | |
| SCHEMBL26205640 | 0.75 | ALDH1A1 (0.34) | KMT2AGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | KMT2A 737/4885SMN1; SMN2 4117/4885MEN1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.